Two appointments to Symphony ViDA board of directors
This article was originally published in Scrip
Executive Summary
Symphony ViDA, a drug development company established in October 2008 by Symphony Capital Partners, in collaboration with the US biopharmaceutical company OXiGENE, to fund and accelerate the development of OXi4503 for oncology and Zybrestat for ophthalmology, has made two appointments to its board of directors: Dr Nicole Onetto, senior vice-president and chief medical officer of ZymoGenetics, and Dr Eric Rowinsky, executive vice-president and chief medical officer of ImClone Systems.